|[November 08, 2012]
Nimbus Discovery and Proteros Enter into Privileged X-Ray Crystallography Partnership Agreement
CAMBRIDGE, Mass. --(Business Wire)--
Nimbus Discovery LLC, today announced that it has executed a Privileged
Partnership Agreement with Proteros Biostructures GmbH ("Proteros"),
Martinsried, Germany. This partnership will accelerate drug discovery
efforts against a growing pipeline of medically important targets.
Nimbus joins a select number of prestigious pharmaceutical and
biotechnology companies that have entered into Privileged Partnership
Agreements with Proteros. Privileged Partners are able to preferentially
access Proteros' new Gallery Structures, technologies and extensive
in-house expertise to accelerate structure-based drug discovery efforts.
Jonathan Montagu, Vice President, Business Development and Operations at
Nimbus commented, "Our cutting-edge computational platform relies
heavily upon high quality x-ray structure data. Hence, our current
collaboration with Proteros has been instrumental in our success with
previously inaccessible targets. This expanded partnership is a logical
progression of how we are integrating leading edge technologies to
create a new model for drug discovery."
Cony D'Cruz, Chief Business Officer and President, Proteros, US Inc.
added, "We are excited to expand our collaboration with Nimbus. The
relationship has been very productive and we look forward to continuing
to support Nimbs' innovative and proven discovery platform."
Nimbus Discovery, a biotechnology company, harnesses cutting-edge
computational technologies to uncover breakthroughs in small molecule
pharmacology. We focus on medically important and highly sought-after
disease targets that have proven inaccessible to traditional industry
approaches. Our robust pre-clinical pipeline includes novel agents for
the treatment of cancer, metabolic disease and inflammation. Nimbus is
organized as a constellation of small, nimble teams of experienced
drug-hunters deployed across program-focused subsidiary companies. Each
team is freed from conventional barriers to scientific success,
chartered to create solutions, and geared for program asset deals with
leading pharmaceutical companies. Founded in 2009, Nimbus partnered with
Schrödinger to invent and apply a physics-based approach that
establishes a new standard for rational drug design. Nimbus is backed by
world-class life science investors; including Atlas Venture, SR One,
Lilly Ventures and Gates Ventures. For more information please visit www.nimbusdiscovery.com.
About Proteros biostructures GmbH:
Proteros is a privately held company that provides services and
proprietary technologies to support integrated drug discovery. Proteros
uses its technical expertise, industrial processes and unique
technologies for crystallography, kinetic and thermodynamic profiling
and fragment-based lead generation incorporating protein structure
inspired compound and fragment libraries. The platform enables
'knowledge driven lead engineering' to accelerate and improve protein
structure analysis and structure-based drug discovery. Proteros
complements its clients' internal capabilities with external expertise
and access to flexible resources. Proteros currently provides services
to more than 80 pharmaceutical and biotechnology clients in North
America, Europe and Asia. Proteros US, Inc. is a wholly owned subsidiary
of Proteros established to serve the growing customer base in North
America. For more information please visit www.proteros.com.
[ Back To TMCnet.com's Homepage ]